Introduction/objective: The NKF-K/DOQI guidelines recommend that the repermeabilisation of thrombosed arteriovenous (AV) grafts for haemodialysis must achieve positive results in 40% at 3 months, if it is performed by endovascular technique, or 50% at 6 months and 40% at one year if it is performed by surgical procedure. This study assesses the results of a hybrid treatment (minimally invasive surgical and endovascular treatment) of AV graft thrombosis associated to venous anastomotic stenosis.

Patients And Method: Between 2008 and 2012, 27 consecutive patients underwent surgery (average age: 69.7, 52% male) due to AV graft thrombosis associated to venous anastomotic stenosis (74.1% upper extremity) by open thrombectomy (mini-incision in the graft), covered self-expanding stent (Fluency, Bard), and high pressure angioplasty (>20atm).

Results: Immediate patency with effective haemodialysis was 89%, with an average stay of 1.9 days and no postoperative complications. Primary patency at 3, 6, and 12 months was 51.9%, 44.4%, and 16.2% respectively (mean follow-up: 15 months). Secondary patency after a new thrombotic episode and similar procedure (62.9% of cases) was 70.4%, 51.9%, and 37% respectively.

Conclusions: Despite being safe and minimally invasive, this hybrid treatment for AV graft thrombosis associated to venous anastomotic stenosis only achieves competitive results compared to open surgery after a second iterative procedure. Because of this and the associated costs, this technique should be reserved for difficult surgical approach stenoses.

Download full-text PDF

Source
http://dx.doi.org/10.3265/Nefrologia.pre2012.Nov.11756DOI Listing

Publication Analysis

Top Keywords

graft thrombosis
16
thrombosis associated
16
associated venous
16
venous anastomotic
16
anastomotic stenosis
12
hybrid treatment
8
minimally invasive
8
treatment graft
8
graft
5
associated
5

Similar Publications

Apheresis is essential to conducting hematopoietic cell transplantation and genetically engineered cellular therapy procedures. Many patients and donors require central venous catheter (CVC) access for apheresis due to lack of adequate peripheral venous access. CVC placement has risks of associated complications and requires additional institutional resources and expertise.

View Article and Find Full Text PDF

Impact of Warfarin and Dual Antiplatelet Therapy on Graft Failure After Coronary Endarterectomy: A Retrospective Cohort Study.

Cardiovasc Drugs Ther

January 2025

Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, The Department of Cardiovascular Surgery, Guangdong Cardiovascular Institute, Guangzhou, Guangdong Province, China.

Purpose: Coronary endarterectomy combined with coronary artery bypass grafting (CE-CABG) effectively achieves coronary revascularization in patients with diffuse atherosclerotic coronary artery disease (CAD). However, the loss of the subendothelial tissue at the CE-CABG coronary artery accelerates local thrombosis, leading to CE-CABG graft failure. Dual antiplatelet therapy (DAT) and warfarin plus aspirin (WPA) are the two most common anticoagulation strategies post CE-CABG.

View Article and Find Full Text PDF

CPSF6-RARγ interacts with histone deacetylase 3 to promote myeloid transformation in RARG-fusion acute myeloid leukemia.

Nat Commun

January 2025

National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, 215006, China.

Acute myeloid leukemia (AML) with retinoic acid receptor gamma (RARG) fusions, which exhibits clinical features resembling acute promyelocytic leukemia (APL), has been identified as a new subtype with poor clinical outcomes. The underlying mechanism of RARG-fusion leukemia remains poorly understood, and needs to be explored urgently to instruct developing effective therapeutic strategies. Here, using the most prevalent RARG fusion, CPSF6-RARG (CR), as a representative, we reveal that the CR fusion, enhances the expansion of myeloid progenitors, impairs their maturation and synergizes with RAS mutations to drive more aggressive myeloid malignancies.

View Article and Find Full Text PDF

Management of Preoperative Recipient Portal Vein Thrombosis in Living-donor Liver Transplantation.

J Clin Exp Hepatol

November 2024

Aster Integrated Liver Care, Aster Medcity, Cheranallur, Kochi 682027, India.

Portal vein thrombosis (PVT) occurs as a part of the natural history of cirrhosis in up to 15% of patients with cirrhosis. In the initial days, PVT was considered a contraindication to liver transplantation, but now with advanced techniques and perioperative management, patients with complex PVT also undergo living-donor liver transplantation (LDLT) with a similar outcome. This review provides a comprehensive overview of methods to proceed with liver transplantation when the recipient has PVT.

View Article and Find Full Text PDF

Background: Spinal tuberculosis is a common cause of spinal deformity and neurological dysfunction, with surgical treatment being crucial in severe cases. This study evaluates the efficacy and safety of combined anterior and posterior surgery with autologous tricortical iliac bone and rib grafting for treating spinal tuberculosis.

Methods: We included 61 patients with thoracic tuberculosis, who underwent a surgical procedure involving initial posterior correction, followed by anterior debridement and reconstruction with autologous tricortical iliac bone and rib grafts.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!